Ophthalmologic signs in mucopolysaccharidoses: Two case reports;Un point d'appel ophtalmologique à l'origine du diagnostic de deux cas de mucopolysaccharidose

Journal Francais d'Ophtalmologie

Volumn 30, Issue 2, 2007, Pages 165-169

  Lala Gitteau, E ^a   Majzoub, S ^a   Labarthe, F ^b   Blesson, S ^b   Pisella, P J ^a  

^a CHU BRETONNEAU   (France)

^b UNIVERSITY HOSPITAL OF TOURS   (France)

Author keywords

Corneal clouding; Hurler's syndrome; Lysosomal disease; Mucopolysaccharidosis; Scheie's syndrome; Storage disease

Indexed keywords

EID: 33847319635     PISSN: 01815512     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0181-5512(07)89568-4     Document Type: Article

References (29)

1. Ashworth J, Biswas S, Wraith E, Lloyd I. Mucopolysaccharidoses and the eye. Surv Ophthalmol, 2006;51:1-17.
2. Guffon N. La mucopolysaccharidose type I (MPS I) : présentation clinique et traitement actuel. Mt pédiatrie, 2003;6:91-7.
3. Kakkis E, Muenzer J, Tiller G, Waber L, Belmont J, Passage M, et al. Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med, 2001;344:182-8.
4. Neufeld E, Muenzer J. The mucopolysaccharidoses. In: Scriver C, Beaudet A, Sly W, Valle D, eds. The metabolic and molecular bases of inherited disease., 7th ed: McGraw-Hill, Medical Publishing Division, 1995.
5. Scott H, Bunge S, Gal A, Clarke LA, Morris CP, Hopwood JJ. Molecular genetics of mucopolysaccharidosis type I: diagnostic, clinical, and biological implications. Hum Mutat, 1995;6:288-302.
6. Ashworth J, Biswas S, Wraith E, Lloyd I. The ocular features of the mucopolysaccharidoses. Eye, 2006;20:553-63.
7. Eibschitz-Tsimhoni M. Ocular manifestations of inherited diseases. In: Springer, ed. Pediatric ophthalmology and strabismus, 2003.
8. Burillon C, Pey C, Durand L. Kératoplastie perforante et dystrophie cornéenne dans le syndrome de Scheie. J Fr Ophtalmol, 1989;12:561-8.
9. Girard B, Hoang-Xuan T, D'Hermies F, Salvodelli M, Bennouna M, Poenaru L, et al. Mucopolysaccharidose de type I, phénotype Hurler-Scheie avec atteinte oculaire. Étude clinique et ultrastructurale. J Fr Ophtalmol, 1994;17:286-95.
10. Tremblay M, Dube I, Gagne R. Altérations de la cornée dans la maladie de Scheie (Mucopolysaccharidose type IS). Étude ultrastructurale. J Fr Ophtalmol, 1979;2:193-7.
11. Collins M, Traboulsi E, Maumenee I. Optic nerve head swelling and optic atrophy in the systemic mucopolysaccharidoses. Ophthalmology, 1990;97:1445-9.
12. Caruso R, Kaiser-Kupfer M, Muenzer J, Ludwig IH, Zasloff MA, Mercer PA. Electroretinographic findings in the mucopolysaccharidoses. Ophthalmology, 1986;93:1612.
13. Moores C, Rogers J, McKenzie I, Brown T. Anesthesia for children with mucopolysaccharidoses. Anesth Intensive Care, 1996;24:459-63.
14. Nicolson S, Black A, Kraras C. Management of a difficult airway in a patient with Hurler-Scheie syndrome during cardiaque surgery. Anesth Analg, 1992;75:830-2.
15. Walker R, Darowki M, Morris P, Wraith J. Anesthesia and mucopolysaccharidosis: A review of Airway problems in a children. Anesthesia, 1994;49:1078-84.
16. Wilder R, Belani K. Fiberoptic intubation complicated by pulmonaire odema in a 12 years-old child with Hurler syndrome. Anesthesiology, 1990;72:205-7.
17. Hall C, Liebaers I, Natale PD, Neufeld E. Enzymatic diagnosis of the genetic mucopolysaccharide storage disorders. Methods Enzymol, 1978;50:439.
18. Kresse H, Figura KV, Klein U, Glossl J, Paschke E, Pohlmann R. Enzymatic diagnosis of the genetic mucopolysaccharide storage disorders. Methods Enzymol, 1982;83:559.
19. Neufeld E, Muenzer J. The mucopolysaccharidoses. In: Scriver C, Beaudet A, Sly W, et al. Eds. The metabolic and molecular bases of inherited disease, 8th ed: McGraw-Hill, Medical Publishing Division, 2001; v. III.
20. Grewal S, Wynn R, Abdenur J, Burton BK, Gharib M, Haase C, et al. Safety and efficacity of enzyme replacement therapy in combination with hematopoietic stem cell transplantation in Hurler syndrome. Genet Med, 2005;7:143-6.
21. Wraith J, Clarke L, Beck M, Kolodny EH, Pastores GM, Muenzer J, et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, doubled-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). J Pediatr, 2004;144:581-8.
22. Sardon O, Garcia Pardos C, Mintegui J, Perez Ruiz E, Coll MJ, Chabas A, et al. Outcome of two patients with Hurler's syndrome under enzyme replacement therapy, with human recombinant alpha-L-iduronidase. An Pediatr, 2005;63:61-7.
23. Ciron C, Desmaris N, Colle M, Raoul S, Joussemet B, Verot L, et al. Gene therapy of the brain in the dog model of Hurler's syndrome. Ann Neurol, 2006;60:204-13.
24. Hoffmann B, Mayatepek E. Neurological manifestations in lysosomal storage disorders - from pathology to first therapeutic possibilities. Neuropediatrics, 2005;36:285-9.
25. Guffon N, Souillet G, Maire I, Straczek J, Guibaud P. Follow-up of nine patients with urler syndrome after bone marrow transplantation. J Pediatr, 1998;133:119-25.
26. Souillet G, Guffon N, Maire I, Pujol M, Taylor P, Sevin F, et al. Outcome of 27 patients with Hurler's syndrome transplanted from either related or unrelated haemotopoietic stem cell sources. Bone Marrow Transplant, 2003;31:1105-17.
27. Gullingsrud E, Krivit W, Summers C. Ocular abnormalities in the mucopolysaccharidoses after bone marrow transplantation. Longer follow-up. Ophthalmology, 1998;105:1099-105.
28. Wraith J. The first 5 years of clinical experience with laronidase enzyme replacement therapy for mucopolysaccharidosis I. Expert Opin Pharmacother, 2005;6:489-506.
29. Terlato N, Cox G. Can mucopolysaccharidosis type I disease severity be predicted based on a patient's genotype? A comprehensive review of literature. Genet Med, 2003;5:286-94.